A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis

Author:

Pandey Krishna,Pal Biplab1,Siddiqui Niyamat Ali2,Lal Chandra Shekhar3,Ali Vahab4,Bimal Sanjiva5,Kumar Ashish6,Verma Neena7,Das Vidya Nand Rabi,Singh Shubhankar Kumar4,Topno Roshan Kamal8,Das Pradeep6

Affiliation:

1. Department of Pharmacology, Lovely Professional University, Phagwara, Punjab,

2. Department of Biostatistics, Lovely Professional University, Phagwara, Punjab,

3. Department of Biochemistry, Lovely Professional University, Phagwara, Punjab,

4. Department of Microbiology, Lovely Professional University, Phagwara, Punjab,

5. Department of Immunology, Lovely Professional University, Phagwara, Punjab,

6. Department of Molecular Biology, Lovely Professional University, Phagwara, Punjab,

7. Department of Pathology, Lovely Professional University, Phagwara, Punjab,

8. Department of Epidemiology, Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Patna, Bihar, India

Abstract

Background: Treatment of post-kala-azar dermal leishmaniasis cases is of paramount importance for kala-azar elimination; however, limited treatment regimens are available as of now. Aim: To compare the effectiveness of liposomal amphotericin B vs miltefosine in post-kala-azar dermal leishmaniasis patients. Methodology: This was a randomized, open-label, parallel-group study. A total of 100 patients of post kala azar dermal leishmaniasis, aged between 5 and 65 years were recruited, 50 patients in each group A (liposomal amphotericin B) and B (miltefosine). Patients were randomized to receive either liposomal amphotericin B (30 mg/kg), six doses each 5 mg/kg, biweekly for 3 weeks or miltefosine 2.5 mg/kg or 100 mg/day for 12 weeks. All the patients were followed at 3rd, 6th and 12th months after the end of the treatment. Results: In the liposomal amphotericin B group, two patients were lost to follow-up, whereas four patients were lost to follow-up in the miltefosine group. The initial cure rate by “intention to treat analysis” was 98% and 100% in liposomal amphotericin B and miltefosine group, respectively. The final cure rate by “per protocol analysis” was 74.5% and 86.9% in liposomal amphotericin B and miltefosine, respectively. Twelve patients (25.5%) in the liposomal amphotericin B group and six patients (13%) in the miltefosine group relapsed. None of the patients in either group developed any serious adverse events. Limitations: Quantitative polymerase chain reaction was not performed at all the follow-up visits and sample sizes. Conclusion: Efficacy of miltefosine was found to be better than liposomal amphotericin B, hence, the use of miltefosine as first-line therapy for post-kala-azar dermal leishmaniasis needs to be continued. However, liposomal amphotericin B could be considered as one of the treatment options for the elimination of kala-azar from the Indian subcontinent.

Publisher

Scientific Scholar

Subject

Infectious Diseases,Dermatology

Reference20 articles.

1. Post-kala-azar dermal leishmaniasis;Zijlstra;Lancet Infect Dis,2003

2. Development of post-Kala-Azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis;Das;Am J Trop Med Hyg,2009

3. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India;Pandey;J Clin Microbiol,2012

4. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India;Burza;PLoS Negl Trop Dis,2014

5. PKDL development after combination treatment with miltefosine and paromomycin in a case of visceral leishmaniasis: First ever case report;Das;J Med Microbiol Immunol Res,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3